Clearpoint Neuro, Inc. — Filing Summary
Issuer and period: The supplied filing is MRI Interventions, Inc.’s Form 10-K for the fiscal year ended December 31, 2018, filed April 1, 2019. The filing does not identify Clearpoint Neuro, Inc. as the issuer, and it reports annual results rather than standalone fourth-quarter results. The figures below are for MRI Interventions; Q4-only financial values are not provided clearly in the supplied text.
Business context
MRI Interventions develops and commercializes MRI-guided minimally invasive surgical platforms. Its commercial ClearPoint system supports brain procedures; ClearTrace, a cardiac product candidate, remained in development with reduced spending as resources were focused on ClearPoint. ClearPoint 2.0 received FDA clearance in November 2018 and was in limited market release. The PURSUIT Neuro Aspiration System received FDA clearance in January 2019.
Financial performance and liquidity
| Metric | FY 2018 | FY 2017 | Change / context |
|---|---|---|---|
| Total revenue | $7.35 million | $7.38 million | Down less than 1% |
| Product revenue | $6.69 million | $7.02 million | Down 5% |
| Service and other revenue | $668,000 | $356,000 | Up 88% |
| Gross margin | 67% | 61% | Improved on favorable sales mix |
| Operating loss | $5.25 million | $6.34 million | Loss narrowed |
| Net loss | $6.16 million | $7.17 million | Loss narrowed 14% |
| Net loss per share | $0.56 | $0.93 | Basic and diluted |
| Cash used in operations | $4.63 million | $5.99 million | Cash burn decreased |
| Cash and equivalents at year-end | $3.10 million | $9.29 million | Down $6.19 million |
| Total assets | $7.86 million | $13.90 million | |
| Stockholders’ equity | $1.51 million | $5.83 million |
Functional neurosurgery revenue was approximately $5.4 million, down 2%; biologics and drug-delivery revenue rose to approximately $1.1 million from $405,000; and capital-equipment revenue fell 62% to $420,000. Cost of revenues declined to $2.43 million from $2.90 million. R&D expense decreased 18% to $2.31 million, sales and marketing fell 11% to $3.53 million, and general and administrative expense rose 7% to $4.33 million. Net interest expense increased to $980,000.
At December 31, 2018, current assets were $6.65 million and current liabilities were $2.01 million. The balance sheet reported $1.54 million of 2010 secured notes and $1.94 million of 2014 secured notes, net of discounts and financing costs, plus $858,000 of accrued interest. Face principal scheduled for 2020 totaled $4.975 million: $3.0 million on the 2010 notes and $1.975 million on the 2014 notes. The 2014 notes bear 12% interest and are secured by a first-priority lien on company assets; the 2010 notes bear 3.5% and are subordinated. The company repaid its $2.0 million Brainlab note in September 2018.
Material changes, outlook, and risks
- Management attributed weaker functional neurosurgery kit sales partly to FDA actions affecting third-party laser-ablation providers and the delayed MRI-suite clearance of a competing DBS system. Both issues were resolved or cleared during 2018.
- Management expects revenue growth from greater use at existing sites and new ClearPoint installations, with operating losses and operating cash use declining. It also expects to continue consuming cash for at least the next 12 months; no specific numerical guidance was provided.
- The auditor’s report and management’s disclosures state that substantial doubt exists about the company’s ability to continue as a going concern. The company says additional financing is necessary, with no assurance it can obtain adequate funding on acceptable terms; equity financing could dilute shareholders.
- Customer concentration is material: the four largest customers represented approximately 27% of revenue, and most sales were not covered by long-term volume commitments. The company also relies on single-source suppliers for many components and conducts substantially all operations at its Irvine facility.
- Key adoption risks include hospital MRI-suite availability, reimbursement and hospital economics, limited clinical evidence, competition, and the company’s limited sales history. ClearPoint products are not separately reimbursed under current Medicare arrangements described in the filing.
- ClearTrace had no regulatory submission and required substantial further development. The filing also identifies regulatory, product-liability, intellectual-property, privacy, and healthcare-compliance risks.
- Other notable items: 2018 included $64,000 of gains from changes in derivative fair value; no derivative liabilities remained at year-end. The company entered into CLS license/collaboration and distribution agreements in October 2018, including minimum purchase commitments. Management reported effective disclosure controls and internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer and filing-period mismatch: this is MRI Interventions, Inc.’s FY 2018 10-K, not a Clearpoint Neuro filing or a standalone Q4 report.
- Assess cash runway, financing availability, and the going-concern warning against current cash burn and the 2020 debt maturities, interest, and secured claims.
- Track whether ClearPoint utilization, new installations, and recurring disposable sales recover following 2018 procedure-volume disruptions.
- Verify the commercial progress and financial terms of ClearPoint 2.0, PURSUIT, and the CLS agreements, including purchase commitments and regulatory or market milestones.
- Review customer concentration, reimbursement support, supplier continuity, and potential dilution from future capital raises and outstanding options and warrants.